Cardiac interventions in patients with achondroplasia: a systematic review

Amrita Sukhavasi1, Thomas J O'Malley1, Elizabeth J Maynes1

  • 1Division of Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Insights

Cardiac interventions in patients with dwarfism, including achondroplasia, show promising safety outcomes. This systematic review highlights that common cardiac procedures can be performed effectively, with necessary equipment adjustments for this unique population.

Area of Science:

  • Cardiology
  • Genetics
  • Surgical Innovation

Background:

  • Patients with achondroplasia and other forms of dwarfism exhibit higher cardiovascular disease rates.
  • Limited research exists on cardiac surgical or percutaneous intervention outcomes in this population.

Purpose of the Study:

  • To systematically review and analyze outcomes of cardiac interventions in patients with dwarfism.
  • To identify challenges and necessary adaptations for cardiac procedures in this unique patient group.

Main Methods:

  • Systematic electronic literature search for achondroplasia, dwarfism, and cardiac intervention.
  • Inclusion of 14 articles detailing 14 patient cases.
  • Extraction and analysis of patient-level data, including demographics, comorbidities, and procedural details.

Main Results:

  • Median age 55.5 years, height 102.0 cm; 57.1% male.
  • Common comorbidities included coronary artery disease (53.8%) and prior myocardial infarction (30.8%).
  • Cardiac surgeries included coronary artery bypass grafting, aortic valve replacement, and aortic dissection repair; no mortality reported.

Conclusions:

  • Common cardiac procedures appear to be safe for patients with dwarfism.
  • Procedural success may require specific equipment modifications to accommodate patient anatomy.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
283
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
284
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
230
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
343
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
182
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
265